aiGENE provides a universal blood test that quantifies tumor markers and evaluates cancer therapy effectiveness through biomarker analysis. This technology delivers critical insights into treatment responses, enabling patients and healthcare providers to make informed clinical decisions.
Funding
$250K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for evaluating cancer therapy effectiveness, such as scans, can take months to show results and may be inaccurate, leading to patients remaining on ineffective treatments with significant side effects and costs. Existing personalized medicine approaches for predicting therapy effectiveness are often inaccurate, particularly for advanced cancers.
Solution
aiGENE offers TheraScape, a blood test that directly measures cancer DNA levels to provide a rapid assessment of cancer treatment effectiveness. The test utilizes an "aiELECTRODE" that is selectively sensitive to altered methylation patterns characteristic of cancer DNA. By measuring the global physical-chemistry change on DNA, TheraScape provides a direct electrical readout, replacing expensive and time-consuming sequencing methods. This technology enables early identification of ineffective therapies, allowing for timely adjustments to treatment plans and potentially improving patient outcomes.
Target Audience
The primary target audience includes pharmaceutical companies conducting clinical trials, CLIA labs, oncologists, and cancer patients seeking timely and accurate information on treatment effectiveness.
Features
- Measures cancer DNA levels directly from a blood sample.
- Employs an "aiELECTRODE" sensitive to cancer-specific methylation patterns.
- Provides a direct electrical readout, eliminating the need for sequencing.
- Offers a rapid assessment of treatment effectiveness, potentially before a second dose of therapy.
- Aims to enable on-site testing in oncologist offices in the future.